Search | Clinical Trials Finder

Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions: Onvansertib, FOLFIRI, Bevacizumab, FOLFOX; Drug
Lead sponsor: Cardiff Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Conditions: Acute Myeloid Leukemia
Interventions: Pracinostat, Placebos, Azacitidine; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more

Conditions: Myasthenia Gravis
Interventions: Placebo, 250 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 15
States / cities: Fresno, California • Orange, California • San Francisco, California + 12 more

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza, Pneumonia
Interventions: oseltamivir; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 1,107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: Louisville, Kentucky

Conditions: HIV Infection, Adherence, Medication, Adherence, Treatment, Pre-Exposure Prophylaxis, Antiretroviral Therapy
Interventions: Next-generation Reader and ID-Cap System, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART); Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cocaine Dependence
Interventions: Galantamine, Computer Assisted Cognitive Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Bridgeport, Connecticut • Stratford, Connecticut

Conditions: Acute Coronary Syndrome
Interventions: Polypill; Combination Product
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Short Bowel Syndrome
Interventions: Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection; Drug · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obstructive Sleep Apnea
Interventions: N-acetylcysteine (NAC), Placebo, Positive Airway Pressure (PAP) Therapy; Dietary Supplement · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Ixazomib, Placebo, Dexamethasone, Lenalidomide; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 78
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more

Conditions: Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions: Standard care, Metformin, Placebo; Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 20 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Multiple Myeloma
Interventions: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more

Conditions: Barrett Esophagus, GERD
Interventions: Cytosponge, Transnasal Endoscopy (TNE), Esophagogastroduodenoscopy; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Adenocarcinoma of the Prostate
Interventions: Muscadine Plus, Placebos; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 13
States / cities: Duarte, California • La Jolla, California • Aurora, Colorado + 10 more

Conditions: HIV Infections
Interventions: tipranavir, ritonavir, Optimized Background Regimen (OBR); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 16
States / cities: Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more

Conditions: Schizophrenia
Interventions: SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more

Conditions: Obesity
Interventions: Traditional food; Other
Lead sponsor: Alaska Native Tribal Health Consortium; Other
Eligibility: 0 Years and older
Enrollment: 416 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Hypertension, Adherence, Medication
Interventions: Medication Adherence Problem Solving for Hypertension; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions: MitoQ, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Belmont, Massachusetts

Conditions: Dentin Sensitivity
Interventions: Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0), Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5), Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 ); Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Graves Disease, Graves' Disease, Hyperthyroidism
Interventions: Ergocalciferol 50,000 IU, Methimazole; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 9 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Hyde Park, New York

Search by objective public record fields.

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

Rapid Empiric Treatment With Oseltamivir Study (RETOS)

Next Generation Ingestible Sensors for Medication Adherence Measurement

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

A Polypill for Acute Coronary Syndrome

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

rHGH and Intestinal Permeability in Intestinal Failure

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Metformin to Augment Low Milk Supply (MALMS) Study

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

Muscadine Plus (MPX) In Men With Prostate Cancer

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Back to Basics: Addressing Childhood Obesity Through Traditional Foods in Alaska

Testing Feasibility of Medication Adherence Problem Solving for Hypertension

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.

Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease